0001484612-23-000002.txt : 20230104 0001484612-23-000002.hdr.sgml : 20230104 20230104171513 ACCESSION NUMBER: 0001484612-23-000002 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230103 FILED AS OF DATE: 20230104 DATE AS OF CHANGE: 20230104 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Vazquez Martin CENTRAL INDEX KEY: 0001823380 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39513 FILM NUMBER: 23507895 MAIL ADDRESS: STREET 1: 3052 ORCHARD DR. CITY: SAN JOSE STATE: CA ZIP: 95134 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Outset Medical, Inc. CENTRAL INDEX KEY: 0001484612 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 200514392 STATE OF INCORPORATION: DE BUSINESS ADDRESS: STREET 1: 3052 ORCHARD DRIVE CITY: SAN JOSE STATE: CA ZIP: 95134 BUSINESS PHONE: 669-231-8200 MAIL ADDRESS: STREET 1: 3052 ORCHARD DRIVE CITY: SAN JOSE STATE: CA ZIP: 95134 FORMER COMPANY: FORMER CONFORMED NAME: Home Dialysis Plus, Ltd. DATE OF NAME CHANGE: 20100219 4 1 edgardoc.xml PRIMARY DOCUMENT X0306 4 2023-01-03 0 0001484612 Outset Medical, Inc. OM 0001823380 Vazquez Martin 3052 ORCHARD DRIVE SAN JOSE CA 95134 0 1 0 0 Chief Operating Officer Common Stock 2023-01-03 4 M 0 5000 3.88 A 54290 D Common Stock 2023-01-03 4 S 0 5000 26.1432 D 49290 D Performance Options (right to buy) 3.88 2023-01-03 4 M 0 5000 0.0 D 2027-12-19 Common Stock 5000 73007 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 1, 2022. The price reported in Column 4 is a weighted average price. The shares of common stock of the Issuer were sold in multiple transactions at prices ranging from: $25.00 - $25.99 - 1,991 shares; $26.00 - $26.99 - 3,009 shares. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold within the range set forth in this footnote. In March 2021, following the expiration of the lock-up period in connection with our initial public offering, the applicable performance and market-based vesting conditions were met and the shares underlying this stock option award became fully vested. By: John L Brottem For: Martin Vazquez 2023-01-04